pharma
Scientists use duoCAR-T therapy to fight HIV
August 9, 2019Medical Communications AIDS, CAR-T therapy, HIV, health, immunotherapy, pharma
Researchers from the University of Pittsburgh, working with the biotech Lentigen, have found that an advanced form of CAR-T therapy …
AstraZeneca’s Tagrisso improves overall survival in lung cancer in Phase 3 trial
August 9, 2019Medical Communications AstraZeneca, Cancer, Tagrisso, lung cancer, oncology, pharma
AstraZeneca has said its cancer drug Tagrisso significantly improved overall survival in a Phase 3 study of patients with lung …
Bayer buys BlueRock Therapeutics for $600 million
August 9, 2019Medical Communications Bayer, BlueRock, acquisitions, cell therapies, pharma
Bayer has entered into an agreement to fully acquire engineered cell therapy firm BlueRock Therapeutics in a deal worth $600 …
Transgene terminates oncolytic IO combo trial in advanced liver cancer
August 8, 2019Research and Development Cancer, Transgene, clinical trials, liver cancer, pharma
Biotech firm Transgene has announced its decision to terminate a study investigating the efficacy of its oncolytic immunotherapy product Pexa-Vec …
Medicare will cover CAR-T therapies in United States
August 8, 2019Sales and Marketing CAR-T therapies, Cancer, Gilead, Kymriah, Medicare, Novartis, keytruda, pharma
Medicare will cover the cost of Novartis’ and Gilead’s CAR-T therapies Kymriah and Yescarta, the US Centers for Medicare and …
Keytruda/chemo combo recommended for first-line lung cancer via Cancer Drugs Fund
August 8, 2019Sales and Marketing CDF, Cancer, MSD, NHS, NICE, UK, keytruda, lung cancer, pharma
MSD’s Keytruda (pembrolizumab) has secured recommendation from NICE for inclusion on the Cancer Drugs Fund (CDF) in combination with chemotherapy …
Gilead’s PrEP drug Descovy should be approved for men and transgender women but not cis-gender women, FDA advisory panel says
August 8, 2019Research and Development AIDS, Gilead, HIV, PrEP, descovy, pharma
Independent experts on a panel advising the FDA have voted in favour of Gilead’s new PrEP drug Descovy in men …
Rhythm Pharma’s obesity drug shows positive results in two Phase 3 trials
August 8, 2019Research and Development Rhythm pharma, clinical trial, health, obesity, pharma
Rhythm Pharma’s obesity drug setmelanotide achieved positive results in two pivotal Phase 3 trials. In both studies, setmelanotide met its …
Sanofi’s Dupixent improves skin clearance in paediatric atopic dermatitis
August 7, 2019Research and Development Dupixent, Sanofi, atopic dermatitis, pharma
As the therapy secured approval in Europe for treatment of adolescent patients with moderate-to-severe atopic dermatitis, Sanofi has revealed new …
AstraZeneca’s Lynparza meets primary endpoint in Phase 3 prostate cancer trial
August 7, 2019Research and Development Lynpraza, PARP inhibitor, lynparza, pharma, prostate cancer
AstraZeneca’s PARP inhibitor Lynparza was successful in improving progression free survival in a Phase 3 trial of patients with metastatic …
Medicinal cannabis company Spectrum makes first shipment into UK
August 7, 2019Research and Development Spectrum, UK, cannabis, medicinalcannabis, pharma
Medicinal cannabis company Spectrum Europe has made its first shipment of cannabis into the UK, making it one of the …
Novartis hid faulty data from FDA over $2.1 million gene therapy Zolgensma
August 7, 2019Research and Development AveXis, FDA, Novartis, Zolgensma, gene therapy, pharma
Novartis hid faulty data from the FDA until their drug was approved, according to a statement from Dr Peter Marks, …
Lilly’s Emgality smashes all Phase 3 endpoints in migraine sub-population
August 6, 2019Manufacturing and Production, Research and Development Eli Lilly, Emgality, migraine, pharma
New Phase 3 data have been revealed on Eli Lilly’s Emgality (galcanezumab-gnlm), detailing its success in meeting all of its …
NICE reject Clovis Oncology’s ovarian cancer drug Rubraca
August 6, 2019Manufacturing and Production NHS, NICE, Rubraca, UK, guidance, pharma
Britain’s cost-effectiveness body NICE has chosen not to recommend Clovis Oncology’s cancer drug Rubraca (rucaparib). On 6 August, NICE issued …
Takeda signs deal with Sosei Heptares worth $1.2 billion
August 6, 2019Manufacturing and Production GPCR, Sosei Heptares, Takeda, pharma, sosei
Takeda has entered into a partnership with Sosei Heptares to develop drugs that modulate G protein-coupled receptor (GPCR) targets. The …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
